Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Johnson & Johnson

Johnson & Johnson
Regional

FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis

October 6, 2025October 4, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 …

FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis Read More

Johnson & Johnson
Regional

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis

September 25, 2025September 24, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults …

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis Read More
Johnson & Johnson
Regional

Johnson & Johnson’s Oral Psoriasis Drug Shows Superiority in Phase 3 Trials

September 23, 2025September 21, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 data showing its investigational oral therapy icotrokinra achieved superior skin clearance compared to deucravacitinib in patients with …

Johnson & Johnson’s Oral Psoriasis Drug Shows Superiority in Phase 3 Trials Read More

Johnson & Johnson
Regional

Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success

July 31, 2025July 29, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration, seeking approval to update the labeling for …

Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success Read More
Johnson & Johnson
Regional

Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis

July 24, 2025July 23, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra, a once-daily oral peptide therapy targeting the …

Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis Read More

Johnson & Johnson
Regional

Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis

June 25, 2025June 24, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the …

Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis Read More
Johnson & Johnson
Regional

FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis

May 2, 2025April 30, 2025 - by Timothy Alexander

SPRING HOUSE, PA — On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & Johnson’s cutting-edge FcRn-blocking antibody treatment for generalized myasthenia gravis (gMG). …

FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis Read More

Johnson & Johnson
Regional

Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study

April 6, 2025April 6, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), revealing its effectiveness in treating active psoriatic arthritis (PsA). The …

Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study Read More

Posts pagination

Previous 1 … 3 4

Trending News

  • Lancaster Woman Accused of Trying to Set Home on Fire

  • Parkesburg Woman Arrested on Strangulation Charges

  • Tredyffrin/Easttown Plan Would Shift Elementary Boundaries

  • What Went Wrong at 7 Chester County Restaurants?

  • Camp Saginaw Withdraws New London Township Cell Tower Plan

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Tiffany Michelle Seda

Lancaster Woman Accused of Trying to Set Home on Fire

November 21, 2026November 20, 2026

Police news

Parkesburg Woman Arrested on Strangulation Charges

November 21, 2026November 20, 2026

Court News

Coatesville Woman Pleads Guilty to Voting Illegally Twice

November 20, 2026November 19, 2026

Copyright © 2026 MyChesCo.